Trials / Terminated
TerminatedNCT00745316
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency. This study will also explore: * Disease related quality-of-life * Exercise capacity * Renal function * Concomitant medications
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tonapofylline | Oral Tonapofylline - 2 capsules bid |
| DRUG | Placebo | Oral placebo - 2 capsules bid |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-09-03
- Last updated
- 2023-09-11
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00745316. Inclusion in this directory is not an endorsement.